GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BELLUS Health Inc (NAS:BLU) » Definitions » EV-to-EBITDA

BELLUS Health (BELLUS Health) EV-to-EBITDA : -18.04 (As of Apr. 25, 2024)


View and export this data going back to 2000. Start your Free Trial

What is BELLUS Health EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BELLUS Health's enterprise value is $1,557.42 Mil. BELLUS Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-86.31 Mil. Therefore, BELLUS Health's EV-to-EBITDA for today is -18.04.

The historical rank and industry rank for BELLUS Health's EV-to-EBITDA or its related term are showing as below:

BLU' s EV-to-EBITDA Range Over the Past 10 Years
Min: -318.26   Med: -24.05   Max: 225.58
Current: -18.04

During the past 13 years, the highest EV-to-EBITDA of BELLUS Health was 225.58. The lowest was -318.26. And the median was -24.05.

BLU's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.22 vs BLU: -18.04

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), BELLUS Health's stock price is $14.74. BELLUS Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.720. Therefore, BELLUS Health's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


BELLUS Health EV-to-EBITDA Historical Data

The historical data trend for BELLUS Health's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BELLUS Health EV-to-EBITDA Chart

BELLUS Health Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.63 -12.80 -4.50 -8.55 -9.32

BELLUS Health Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.19 -10.86 -13.32 -9.32 -6.96

Competitive Comparison of BELLUS Health's EV-to-EBITDA

For the Biotechnology subindustry, BELLUS Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BELLUS Health's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BELLUS Health's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BELLUS Health's EV-to-EBITDA falls into.



BELLUS Health EV-to-EBITDA Calculation

BELLUS Health's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1557.421/-86.313
=-18.04

BELLUS Health's current Enterprise Value is $1,557.42 Mil.
BELLUS Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BELLUS Health  (NAS:BLU) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BELLUS Health's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=14.74/-0.720
=At Loss

BELLUS Health's share price for today is $14.74.
BELLUS Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.720.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


BELLUS Health EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BELLUS Health's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BELLUS Health (BELLUS Health) Business Description

Traded in Other Exchanges
N/A
Address
275 Armand-Frappier Boulevard, Laval, QC, CAN, H7V 4A7
BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with a high unmet medical need, including BLU-5937, a P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, the development of drug candidates for health solutions.

BELLUS Health (BELLUS Health) Headlines

From GuruFocus